Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

ENTERO VU 24%

BARIUM SULFATE

Standard Dose
24%
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview ENTERO VU 24% is listed in Drugs@FDA under application 208143 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient BARIUM SULFATE Form and strength SUSPENSION;ORAL - 24% Sponsor BRACCO Submission history Latest submission status date: 2022-03-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview ENTERO VU 24% is listed in Drugs@FDA under application 208143 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient BARIUM SULFATE Form and strength SUSPENSION;ORAL - 24% Sponsor BRACCO Submission history Latest submission status date: 2022-03-10 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.
ENTERO VU 24% (BARIUM SULFATE) | Drug Monograph | MedicHelpline